Interferon-α in high-risk melanoma patients

References

• World Health Organization. INTERSUN — Global UV project (2004).
   Google Scholar
• Cancer Facts & Figures. American Cancer Society (2004).
   Google Scholar
• Howe HL, Wingo PA, Thun MJ et aL Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 93(11), 824–842 (2001).
   Google Scholar
• Berwick M. Patterns of sun exposure which are causal for melanoma. In: Melanoma Critical Debates. Bishop J, Gore M (Eds). Blackwell Science, Oxford, UK, 3–15 (2002).
   Google Scholar
• Crowson AN, Magro CM, Sanchez- Carpintero I, Mihm MC Jr. The precursors of malignant melanoma. In: Cancers of the Skin: Proceedings of the 8th World Congress. Drummer R, Nestle FO (Eds). Springer, NY, USA, 75–84 (2002).
   Google Scholar
• Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-Stage IV melanoma. J. Clin. OncoL 19(11), 2844–2850 (2001).
   Google Scholar
• Geller AC, Annas GD. Epidemiology of melanoma and nonmelanoma skin cancer. Semin. OncoL Nurs. 19(1), 2–11 (2003).
   PubMedGoogle Scholar
• Lotze MT, Dallal RM, Kirkwood JM et aL Cutaneous melanoma. In: Cancer: Principles & Practice of Oncology DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA, 2012-2069 (2001).
   Google Scholar
• American Joint Committee on Cancer. Cancer Staging Handbook from the AJCC Cancer Staging Manual. Springer, NY, USA (2002).
   Google Scholar
• Balch CM, Soong S-J, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J. Clin. OncoL 19(16), 3622–3634 (2001).
   Google Scholar
• Morton DL, Wen DR, Wong JH et aL Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127(4), 392–399 (1992).
   PubMed Web of Science ®Google Scholar
• Reintgen D, Cruse CW, Wells K et aL The orderly progression of melanoma nodal metastases. Ann. Surg. 220 (6), 759–767 (1994).
   PubMed Web of Science ®Google Scholar
• Albertini JJ, Cruse CW, Rapaport D et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann. Surg. 223(2), 217–224 (1996).
   PubMedGoogle Scholar
• Thompson JF, McCarthy WH, Bosch CM et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 5(4), 255–260 (1995).
   Google Scholar
• Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 Stage I or II melanoma patients. J Clin. OncoL 17(3), 976–983 (1999).
   Google Scholar
• Gershenwald JE, Tseng CH, Thompson W et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124(2), 203–210 (1998).
   PubMed Web of Science ®Google Scholar
• Yu LL, Flotte TJ, Tanabe KK et aL Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86(4), 617–627 (1999).
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Colome MI, Lee JE et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with Stage I or II melanoma. J. Clin. OncoL 16(6), 2253–2260 (1998).
   Google Scholar
• Balch CM, Buzaid AC, Soong S-J et aL Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin. OncoL 19(16), 3635–3648 (2001).
   Google Scholar
• Ak I, Stokkel MP, Bergman W, Pauwels EK. Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur. NucL Med. 27(4), 447–458 (2000).
   Google Scholar
• Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann. Surg. OncoL 7(2), 160–165 (2000).
   Google Scholar
• Gershenwald JE, Prieto VG, Colome- Grimmer MI et al. The prognostic significance of microscopic tumor burden in 945 melanoma patients undergoing sentinel lymph node biopsy. Proceedings from the American Society of Clinical Oncology. New Orleans, LA, USA (2000).
   Google Scholar
• Pawlik TM, Sondak VK. Malignant melanoma: current state of primary and adjuvant treatment. Crit. Rev OncoL HematoL 45(3), 245–264 (2003).
   PubMed Web of Science ®Google Scholar
• Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Co-ordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon-a2a in high-risk resected malignant melanoma. Clin. OncoL 22(1), 53–61 (2004).
   Google Scholar
• Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon-a2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358,866–869 (2001).
   PubMed Web of Science ®Google Scholar
• Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A. Interferon-a as adjuvant therapy for melanoma: a meta-analysis of the randomised trials. Proc. Am. Soc. Clin. OncoL (2001).
   Google Scholar
• Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev 29(4), 241–252 (2003).
   Google Scholar
• ••Summarizes all of the clinical trials relatedto high-dose interferon-a (HDI).
   Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon-a2a in high-risk melanoma: first analysis of intergroup trial E1690/59111/C9190. Clin. OncoL 18(12), 2444–2458 (2000).
   Google Scholar
• Cameron DA, Cornbleet MC, Mackie RM et al. Adjuvant interferon-a2a in high risk melanoma — the Scottish study. Br. J. Cancer84(9), 1146–1149 (2001)
   Google Scholar
• Kleeberg UR, Broecker EB, Chartier C et al. Adjuvant trial in melanoma patients comparing rIFN-a to rIEN-r to Iscador to a control group after curative resection of high risk primary (>= 3 mm) or regional lymphnode metastasis (EORTC 18871). Eur. J. Cancer 135 (Suppl. 4), S82 (1999).
   Google Scholar
• Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon-a2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Co-operative Group on Melanoma. Lancet 351,1905-1910 (1998).
   Google Scholar
• Pehamberger H, Sayer HP, Steiner A et al. Adjuvant interferon a2a treatment in resected primary Stage II cutaneous melanoma. Austrian Malignant Melanoma Co-operative Group. J Clin. OncoL 16(4), 1425–1429 (1998).
   Google Scholar
• Creagan ET, Dalton RJ, Ahmann DL et al. Randomized, surgical adjuvant clinical trial of recombinant interferon 0E2a in selected patients with malignant melanoma. J Clin. OncoL 13(11), 2776–2783 (1995).
   Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon ci2b adjuvant therapy of high- risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684.J. Clin. Ont.& 14(1), 7–17 (1996).
   Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et aL High-dose interferon a2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage JIb-III melanoma: results of intergroup trial E1694/59512/C509801. Clin. arca 19(9), 2370–2380 (2001).
   Google Scholar
• Kirkwood JM, Ibrahim J, Lawson DH et aL High-dose interferon a2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Co-operative Oncology Group Phase II Trial E2696.J Clin. arca 19(5), 1430–1436 (2001).
   Google Scholar
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern co-operative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670–1677 (2004).
   PubMed Web of Science ®Google Scholar
• •Pooled analysis of HDI trials with the most recent follow-up data.
   Google Scholar
• Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin. Ont.& 22(1), 7–10 (2004).
   Google Scholar
• Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon a2b. Clin. Ont.& 22(1), 11–14 (2004).
   Google Scholar
• Eggermont AMM, Kleeberg UR, Ruiter DJ, Suciu S. The European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon-a2a. American Society of Clinical Oncology, VA, USA (2001).
   Google Scholar
• Kirkwood JM, Bender C, Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon a2b therapy. J Clin. arca 20(17), 3703–3718 (2002).
   Google Scholar
• ••Discusses in detail the toxicities related toHDI treatment.
   Google Scholar
• Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P Mood and cognitive side effects of interferon-a therapy. Sernim Ont.& 25(1 Suppl. 1), 39–47 (1998).
   Google Scholar
• Kilbridge KL, Cole BF, Kirkwood JM et al. Weeks JC. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon a2b for high-risk melanoma patients using intergroup clinical trial data. I Clin. Ont.& 20(5), 1311–1318 (2002).
   Google Scholar
• Kilbridge KL, Weeks JC, Sober AJ et al. Patient preferences for adjuvant interferon a2b treatment. j Clin. Ont.& 19(3), 812–823 (2001).
   Google Scholar
• ••Reports utilities for HDI collectedprospectively using the Standard Gamble method.
   Google Scholar
• Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon a2b in high-risk melanoma based on projections from Eastern Co-operative Oncology Group 1684.j Clin. Ont.& 15(6), 2351–2358 (1997).
   Google Scholar
• Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur. j Cancer33(9), 1373–1379 (1997).
   PubMedGoogle Scholar
• Gonzalez-Larriba JL, Serrano S, Alvarez- Mon M et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur. J Cancer 36(18), 2344–2352 (2000).
   Google Scholar
• Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon a therapy in Stage III cutaneous melanoma in Quebec. Value Health 7(4), 423–432 (2004).
   PubMed Web of Science ®Google Scholar
• Crott R, Ali F, Burdette-Radoux S. Measurement of utility-based quality-of-life in adjuvant interferon therapy in melanoma. Quality Life Res. 8,284 (1999).
   Google Scholar
• Crott R. Cost effectiveness and cost utility of adjuvant interferon a in cutaneous melanoma: a review. PharmacoEconomics 22(9), 569–580 (2004).
   PubMedGoogle Scholar
• •Review of cost-effectiveness and cost-utility analysis of HDI in patients with Stage II and III melanoma.
   Google Scholar
• Sabel MS, Sondak VK. Is there a role for adjuvant high-dose interferon-a-2b in the management of melanoma? Drugs 63(11), 1053–1058 (2003).
   Google Scholar
• Eggermont AMM, Keilholz U. What is the role of biological response modifiers in the treatment of melanoma? In: Melanoma: Critical Debates. Newton Bishop JA, Gore M (Eds). Blackwell Science Ltd, Oxford, UK, 195–211 (2002).
   Google Scholar
• Retsas S. Adjuvant therapy of malignant melanoma: is there a choice? Crit. Rev arca Hematol. 40(2), 187–193 (2001).
   Google Scholar
• Hersey P. Will vaccines really work for melanoma? In: Melanoma: Critical Debates. Newton Bishop JA, Gore M (Eds). Blackwell Science, Oxford, UK, 212–229 (2002).
   Google Scholar
• Sondak VK, Sosman J, Unger JM et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. Proceedings from the American Society of Clinical Oncology. New Orleans, LA, USA (2004).
   Google Scholar
• Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 80(6), 1052–1064 (1997).
   PubMedGoogle Scholar